Cargando…

Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом

BACKGROUND: BACKGROUND: Gonadotropin therapy in boys with congenital isolated hypogonadotropic hypogonadism helps to increase testes volume and induce spermatogenesis in comparison with testosterone therapy. However, difficulties with dose titration, partial therapy success, absence of generally acc...

Descripción completa

Detalles Bibliográficos
Autores principales: Кокорева, К. Д., Чугунов, И. С., Карева, М. А., Безлепкина, О. Б.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrinology Research Centre 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978876/
https://www.ncbi.nlm.nih.gov/pubmed/36842078
http://dx.doi.org/10.14341/probl13141
_version_ 1784899615876710400
author Кокорева, К. Д.
Чугунов, И. С.
Карева, М. А.
Безлепкина, О. Б.
author_facet Кокорева, К. Д.
Чугунов, И. С.
Карева, М. А.
Безлепкина, О. Б.
author_sort Кокорева, К. Д.
collection PubMed
description BACKGROUND: BACKGROUND: Gonadotropin therapy in boys with congenital isolated hypogonadotropic hypogonadism helps to increase testes volume and induce spermatogenesis in comparison with testosterone therapy. However, difficulties with dose titration, partial therapy success, absence of generally accepted regimen protocols don’t allow to use this therapy in order to induce puberty in adolescents with Kallmann syndrome or normosmic hypogonadotropic hypogonadism. AIM: AIM: To assess the effectiveness of combination hormonal replacement therapy via human chorionic gonadotropin and recombinant follicle stimulation hormone in adolescents with congenital isolated normosmic hypogonadotropic hypogonadism and with Kallmann syndrome MATERIALS AND METHODS: MATERIALS AND METHODS: This is an open single-center prospective non-controlled study. Boys with hypogonadotropic hypogonadism were receiving hormonal replacement therapy for 12 months. Initial dose of human chorionic gonadotropin was 500 IU per week. Initial dose of recombinant follicle stimulation hormone was 37.5 IU per week. Doses were doubled in 6 months. Antropometric data, Tanner stage, testes volumes, inhibin B and anti-Mullerian hormone (AMH) levels were evaluated in all the patients before the treatment, after 6 and 12 months of the therapy. RESULTS: RESULTS: 8 boys with hypogonadotropic hypogonadism were included into the study. Median age before therapy initiation was 15.7 years [15.33; 16.41]. In 12 months after the therapy initiation puberty development, testosterone increase from 0.44 [0.34;0.62] to 4.39 [0.88;10.51] nmol/l (p=0.012), AMH decrease from 35.70 [18.00;59.00] to 14.41 [11.60;16.65] ng/ml were noted in all the patients (p=0.017). Testes volumes increase and inhibin B level increase were not statistically significant. CONCLUSION: CONCLUSION: Gonadotropin therapy is effective in order to puberty initiation in adolescents with congenital hypogonadotropic hypogonadism. In helps to achieve not only androgenization, but also to Sertoli cells maturation.
format Online
Article
Text
id pubmed-9978876
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Endocrinology Research Centre
record_format MEDLINE/PubMed
spelling pubmed-99788762023-03-03 Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом Кокорева, К. Д. Чугунов, И. С. Карева, М. А. Безлепкина, О. Б. Probl Endokrinol (Mosk) Research Article BACKGROUND: BACKGROUND: Gonadotropin therapy in boys with congenital isolated hypogonadotropic hypogonadism helps to increase testes volume and induce spermatogenesis in comparison with testosterone therapy. However, difficulties with dose titration, partial therapy success, absence of generally accepted regimen protocols don’t allow to use this therapy in order to induce puberty in adolescents with Kallmann syndrome or normosmic hypogonadotropic hypogonadism. AIM: AIM: To assess the effectiveness of combination hormonal replacement therapy via human chorionic gonadotropin and recombinant follicle stimulation hormone in adolescents with congenital isolated normosmic hypogonadotropic hypogonadism and with Kallmann syndrome MATERIALS AND METHODS: MATERIALS AND METHODS: This is an open single-center prospective non-controlled study. Boys with hypogonadotropic hypogonadism were receiving hormonal replacement therapy for 12 months. Initial dose of human chorionic gonadotropin was 500 IU per week. Initial dose of recombinant follicle stimulation hormone was 37.5 IU per week. Doses were doubled in 6 months. Antropometric data, Tanner stage, testes volumes, inhibin B and anti-Mullerian hormone (AMH) levels were evaluated in all the patients before the treatment, after 6 and 12 months of the therapy. RESULTS: RESULTS: 8 boys with hypogonadotropic hypogonadism were included into the study. Median age before therapy initiation was 15.7 years [15.33; 16.41]. In 12 months after the therapy initiation puberty development, testosterone increase from 0.44 [0.34;0.62] to 4.39 [0.88;10.51] nmol/l (p=0.012), AMH decrease from 35.70 [18.00;59.00] to 14.41 [11.60;16.65] ng/ml were noted in all the patients (p=0.017). Testes volumes increase and inhibin B level increase were not statistically significant. CONCLUSION: CONCLUSION: Gonadotropin therapy is effective in order to puberty initiation in adolescents with congenital hypogonadotropic hypogonadism. In helps to achieve not only androgenization, but also to Sertoli cells maturation. Endocrinology Research Centre 2023-02-25 /pmc/articles/PMC9978876/ /pubmed/36842078 http://dx.doi.org/10.14341/probl13141 Text en Copyright © Endocrinology Research Centre, 2023 https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 License.
spellingShingle Research Article
Кокорева, К. Д.
Чугунов, И. С.
Карева, М. А.
Безлепкина, О. Б.
Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом
title Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом
title_full Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом
title_fullStr Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом
title_full_unstemmed Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом
title_short Инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом
title_sort инициация пубертата гонадотропинами у мальчиков с врожденным изолированным гипогонадотропным гипогонадизмом
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978876/
https://www.ncbi.nlm.nih.gov/pubmed/36842078
http://dx.doi.org/10.14341/probl13141
work_keys_str_mv AT kokorevakd iniciaciâpubertatagonadotropinamiumalʹčikovsvroždennymizolirovannymgipogonadotropnymgipogonadizmom
AT čugunovis iniciaciâpubertatagonadotropinamiumalʹčikovsvroždennymizolirovannymgipogonadotropnymgipogonadizmom
AT karevama iniciaciâpubertatagonadotropinamiumalʹčikovsvroždennymizolirovannymgipogonadotropnymgipogonadizmom
AT bezlepkinaob iniciaciâpubertatagonadotropinamiumalʹčikovsvroždennymizolirovannymgipogonadotropnymgipogonadizmom